Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
株式のランク #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
株価
$0.28545656
時価総額
$4.50M
変化(1日)
5.97%
変化(1年)
0.00%
FR
取引 Acticor Biotech SAS (ALACT)

カテゴリー

Acticor Biotech SAS(ALACT)のP/B比率
March 2026 時点のP/B比率 TTM: -0.57
Acticor Biotech SAS の最新の財務報告および株価によると、現在のP/B比率(TTM)は -0.57 です。2022 年末時点でのP/B比率は -33.19 でした。
Acticor Biotech SAS の P/B 比率の履歴(2010 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差
5.6573 -1,096.18%
DK
6.3842 -1,224.18%
US
2.4551 -532.31%
US
4.364 -868.45%
BE
2.5504 -549.09%
AU